Paque, M. (10 December 2025). mTORC2-dependent reprogramming of lipid metabolism is a therapeutic vulnerability in lung cancer [Poster presentation]. Tumor Heterogeneity, Plasticity and Therapy (3rd edition). |
Paque, M. (08 October 2025). mTORC2-dependent reprogramming of lipid metabolism is a therapeutic vulnerability in lung cancer [Poster presentation]. Metabolism & Cancer, Montpellier, France. |
Paque, M. (25 September 2025). mTORC2-dependent metabolism is a therapeutic vulnerability in lung cancer [Poster presentation]. Be Precise. |
Paque, M. (25 September 2025). mTORC2-dependent metabolism is a therapeutic vulnerability in lung cancer [Paper presentation]. Be Precise. |
Paque, M. (12 September 2025). mTORC2-dependent reprogramming of lipid metabolism is a therapeutic vulnerability in lung cancer [Poster presentation]. GIGA Day. |
Paque, M. (02 July 2025). mTORC2-dependent metabolism is a therapeutic vulnerability in lung cancer [Poster presentation]. ISCaM Conference. |
Paque, M. (06 June 2025). mTORC2-dependent reprogramming of lipid metabolism is a metabolic vulnerability in lung cancer [Paper presentation]. BeRS-GSK Basic Awards Conference. |
Quarto, G., Li Greci, A., Bizet, M., Penning, A., Primac, I., Murisier, F., Garcia-Martinez, L., Borges, R. L., Gao, Q., Cingaram, P. K. R., Calonne, E., Hassabi, B., Hubert, C., Herpoel, A., Putmans, P., Mies, F., Martin, J., Van der Linden, L., Dube, G., ... Fuks, F. (20 February 2025). Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation. Cell, 188 (4), 998 - 1018. doi:10.1016/j.cell.2024.12.009 |
Paque, M. (29 January 2025). mTORC2-dependent reprogramming of lipid metabolism is a metabolic vulnerability in lung cancer [Poster presentation]. Televie Seminar, Liège, Belgium. |
Paque, M. (25 October 2024). mTORC2-dependent reprogramming of lipid metabolism supports lung cancer progression [Poster presentation]. FNRS Metabolism. |
Paque, M. (25 October 2024). mTORC2-dependent reprogramming of lipid metabolism supports lung cancer progression [Paper presentation]. FNRS Metabolism. |
Paque, M. (18 October 2024). mTORC2-dependent reprogramming of lipid metabolism supports lung cancer progression [Paper presentation]. BACR 2024. |
Paque, M. (13 September 2024). mTORC2-dependent reprogramming of lipid metabolism supports lung cancer progression [Paper presentation]. GIGA Day. |
Paque, M. (13 September 2024). mTORC2 activation drives the reprogramming of lipid metabolism to support lung cancer progression [Poster presentation]. GIGA Day, Liège, Belgium. |
Paque, M. (05 July 2024). mTORC2-dependent reprogramming of lipid metabolism is a metabolic vulnerability in lung cancer [Paper presentation]. ISCaM Conference. |
Paque, M. (27 October 2023). mTORC2-dependent reprogramming of lipid metabolism supports lung cancer progression [Paper presentation]. BACR 2023, Belgium. |
Paque, M. (03 October 2023). mTORC2 activation drives the reprogramming of lipid metabolism to support lung cancer progression [Poster presentation]. Tumor Heterogeneity, Plasticity and Therapy (2nd edition), Leuven, Belgium. |